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ﬁrst-line therapy.
Patients and methods: The study included 35 patients. All patients were assessed for disease
severity using Valiukenas Achalasia Severity (VAS) scoring system and the disease was staged using
Kostic esophageal dilatation (KED) staging system. Patients underwent manometric esophageal
pressure (MEP) measurement. All patients underwent PD. Patients were followed up for
12-months, failure of symptomatic relief or recurrence of symptoms was followed by another PD
attempt or laparoscopic Heller’s myotomy combined with Dor fundoplication and follow-up for
another 12 months.
Results: Twenty-seven patients took their 1st oral intake after 9–12 h and 25 patients (71.5%)
were managed as one-day procedure. At 12-M follow-up, three patients (8.5%) required three
attempts of PD, ﬁve patients (14.3%) required two attempts and 27 patients had only one attempt
to achieve relief of symptoms. At the end of 12-M follow-up period; 26 patients showed sustained
complete relief of symptoms and scored zero on VAS scoring and had stage I on KED staging. For
these 26 the subjective and objective success rate was 74.4%. Nine patients who had failed PD trials
were planned for surgery. Subjective surgical success rate was 66.7% and objective success rate was
77.8%. Comparison of outcome of both modalities showed nonsigniﬁcant subjective improvement
in favor of PD, while surgery showed non-signiﬁcant objective improvement compared to PD.
Conclusion: PD could be considered as safe, effective and cost-effective therapeutic modality for
patients having classic achalasia with high subjective and objective success rate.
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Achalasia cardia is one of the common causes of motor dys-
phagia. Achalasia is characterized by a functional obstruction
of the esophagus caused by failed relaxation of the lower
esophageal sphincter (LES) in combination with absent peri-
stalsis of the distal esophagus. The exact pathogenesis of thisgyptian Society of Ear, Nose, Throat and Allied Sciences.
Table 1 Valiukenas Achalasia Severity Scoring.
Symptoms Score
0 1 2 3
Dysphagia to solids No Weekly Daily Each meal
Dysphagia to liquids No Weekly Daily Each meal
Active regurgitation No Weekly Daily Each meal
Passive regurgitation No Monthly Weekly Daily
Chest pain No Monthly Weekly Daily
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cardia is caused by loss of inhibitory ganglion in the myenteric
plexus of the esophagus. In the initial stage, degeneration of
inhibitory nerves in the esophagus results in unopposed action
of excitatory neurotransmitters such as acetylcholine, resulting
in high amplitude non-peristaltic contractions (vigorous acha-
lasia); progressive loss of cholinergic neurons over time results
in dilation and low amplitude simultaneous contractions in the
esophageal body (classic achalasia).1,2
The proposed causes for the loss of inhibitory nitrinergic
neurons in the esophageal myenteric plexus include genetic
inheritance, neuronal degeneration, viral infection and autoim-
mune disease3–6 and the characteristic symptoms of patients
with achalasia are dysphagia for solids and liquids, regurgita-
tion of undigested food or saliva, respiratory complaints (noc-
turnal cough, aspiration), retrosternal pain and weight loss.7
Therapeutic options aim to improve esophageal emptying
by decreasing LES pressure. There are several treatment op-
tions, either endoscopic procedures including pneumatic bal-
loon dilatation (PD), Botox injection into the LES, stenting,
peroral endoscopic myotomy and surgery (Heller laparoscopic
myotomy) can be used for these purposes.8 Botox injection
inhibits the release of acetylcholine in the myenteric plexus,
although many prospective studies report swift improvement
in symptoms, complaints recurred after 3–12 months, since
its effect is short-lived, Botox treatment is recommended only
for patients with high comorbidity.9 One promising new endo-
scopic procedure is peroral endoscopic myotomy, for which
the short-term results available to date of a prospective study
have shown improvement in symptoms as no complaints after
three months and a signiﬁcant reduction in resting tone of the
LES.10 Endoscopic sclerotherapy with ethanolamine oleate is a
promising alternative to classic therapies for achalasia, but
treated patients showed a trend to ﬁbrosis and clinical recur-
rence so dilation seems particularly effective after endoscopic
sclerotherapy.11
Pneumatic dilatation was chosen as the ﬁrst-line therapy,
despite the wide range of the reported success rates, ranging
from 35% to 85% within several years of follow-up. However,
these marked differences may be partly explained by differ-
ences in the length of follow-up.[12,13] The current prospective
study aimed to determine the outcome of pneumatic dilatation
for cases of achalasia of the cardia as a ﬁrst-line therapy fol-
lowed by laparoscopic Heller’s myotomy in case of failure.
2. Patients and methods
The current study was conducted at Departments of Otorhino-
laryngology andGeneral Surgery, Ain ShamsUniversityHospi-
tal, from June 2007 till June 2012. After approval of the study
protocol by the Local Ethics Committee and obtaining written
fully informed patients’ consent, patients with complaints sug-
gestive of having achalasia of the cardia were included in the
study and subjected to clinical examination, abdominal ultraso-
nography and laboratory investigations. Patients who had asso-
ciated pathology were not enrolled in the study.
Enrolled patients were assessed clinically for disease sever-
ity using Valiukenas Achalasia Severity (VAS) scoring system
(Table 1) with score = 1–5: mild, 6–9: moderate and P10:
severe symptoms. Regurgitation was deﬁned as any sensation
of spontaneous (i.e. passive) or active eructation of gastroin-
testinal contents into the mouth or upper pharynx.14 Allpatients underwent complete upper gastrointestinal barium
study using a low-density barium sulfate suspension and the
stage of the disease was assessed according to the degree of
esophageal dilatation according to Kostic et al.15 as follows:
Stage I: minimal esophageal dilatation of <4 cm, Stage II:
moderate esophageal dilatation of 4 to 6 cm and Stage III: se-
vere esophageal dilatation of >6 cm.
All patients underwent upper gastrointestinal endoscopy un-
der medazolam (2.5–10 mg) intravenous sedation and after top-
ical lignocaine 10% spray anesthesia. Presence of any resistance
at cardia was assessed and biopsy was taken to exclude other
pathologies. Manometric studies for determination of the diag-
nostic manometric ﬁndings including absence of esophageal
peristalsis, elevated LES pressure >30 mmHg, absent, incom-
plete, or complete but shortened (<6 s) relaxation of LES
and elevated intra-esophageal pressure were carried out.
All patients underwent pneumatic dilatation, (Fig. 1) using
40 mmmicrovasive balloon under pressure of 15 psi maintained
for 60 s to produce a complete disruption of the LES muscula-
ture rendering it incompetent so as to release the distal esopha-
geal obstruction and induce symptomatic improvement. To
achieve target therapeutic effect, dilatation to a diameter of at
least 3 cm was performed using incrementally larger balloon
sizes during successive dilatations to lower down the resting
LES pressure to 10 mmHg and duration of the procedure was
determined. Dilation procedure was conducted as outpatient
procedure and patient was observed for 6 h and then oral gast-
rographin swallow was performed to exclude esophageal perfo-
ration. Time of ﬁrst oral intake without complaint was
determined and then, patients were allowed to return home
and total hospital stay time was determined. Patients developed
intra-procedural complications or failed to be satisﬁed with
their ﬁrst oral intake were admitted for further management
Patients were evaluated clinically for VAS scoring at 1
(M-1), 3 (M-3), 6 (M-6) and 12 (M-12) months after PD. Endo-
scopic follow-upwas conducted atM-1,M-6 andM-12 forKos-
tic esophageal dilatation (KED) staging. Manometric
esophageal pressure (MEP) measurements were performed at
M-1,M-3,M-6 andM-12. Patients could not achieve symptom-
atic relief or had recurrence of symptoms at M-1 were re-evalu-
ated and underwent another PD attempt or referred for surgical
interference. Number of PD attempts prior to shift to surgery
was recorded and subjective and objective success was evalu-
ated. Patients’ outcome at end of 12 months was determined.
2.1. Laparoscopic Heller’s myotomy combined with Dor
fundoplication
All surgeries were conducted under general inhalational anes-
thesia. After creation of pneumoperitoneum up to an intra-
Figure 1 Endoscopic photographs of the procedure; inﬂated balloon (black arrows).
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used for conduction of surgery. Myotomy was done for at least
6 cm of distal esophagus and 1.5–2 cm onto the gastric side,
the extent and completeness of the myotomy in addition to
the integrity of the esophageal mucosa were checked by per-
forming per-operative esophagoscopy to localize the squamo-
columnar junction, to assure a widely patent esophagogastric
junction, and distend the distal esophagus with air to visualize
a bulging mucosa without remaining muscular bands. Dor fun-
doplication (anterior fundic wrap) as antireﬂux procedure was
performed after completing the myotomy (Fig. 2a–f).
3. Statistical analysis
Obtained data were presented as mean ± SD, ranges, numbers
and ratios. Results were analyzed using Wilcoxon; ranked test
for unrelated data (Z-test) and Chi-square test (v2 test). Statis-
tical analysis was conducted using the SPSS (Version 15, 2006)
for Windows statistical package. P value < 0.05 was consid-
ered statistically signiﬁcant.4. Results
The study included 35 patients with varied degrees of achalasia;
20 males and 15 females with mean age of 39.5 ± 10.4; range:
23–57 years. According to VAS scoring, only ﬁve patients were
scored 1, 21 patients were scored 2 and nine patients were scored
3. According to KED staging, seven patients were of stage I, 23
patients were of stage II and ﬁve patients were of stage III.
Twenty-nine patients hadMEP > 45 mmHg, while six patients
had esophageal pressure in the range of 30–45 mmHg, (Table 2)
Mean PD procedural time was <45 min in 25 patients
(71.5%), while in 10 patients it ranged between 45 and
60 min. All procedures were completed safely without intraop-erative complications apart from minor mucosal tear recorded
in two patients (5.7%), both patients were managed conserva-
tively with broad-spectrum antibiotics and nothing per oral for
24 h to allow mucosal healing. Twenty-seven patients were al-
lowed to take their 1st oral intake within a range of 9–12 h
after completion of procedure, while eight patients (22.8%)
had their 1st oral intake after more than 12 h. Mean time of
hospital stay was 1.3 ± 0.5 days; 25 patients (71.5%) were
managed as one-day procedure, while 10 patients required hos-
pitalization and were discharged on the next day, (Table 3).
Twenty-seven patients (77.1%) showed relief of symptoms
till the end of 12-m follow-up period after one PD attempt.
On M-1, MEP measurement deﬁned six patients (17.1%) had
relapsed elevation of pressure but was in range of
30–45 mmHg and a second PD attempt was carried on. On
M-6 MEP measurement, ﬁve patients (14.3%); three of those
who had their second attempt at M-1 and two new patients
had relapsed elevation of MEP but was in the range of
30–45 mmHg and a second PD attempt was carried on for
the newly diagnosed patients and a third attempt was carried
on for the secondly relapsing patients. Thus, at the end of
12-m follow-up, three patients (8.5%) required three attempts
of PD, ﬁve patients (14.3%) required two attempts and 27
patients had only one attempt, (Fig. 3).
At the end of 12-M follow-up period; 26 patients showed
sustained complete relief of symptoms and were scored zero
on VAS scoring, and had stage I on KED staging. Moreover,
all of these 26 patients had mean MEP of 19.2 ± 3.6; range:
14–27 mmHg; thus, PD showed a subjective and objective suc-
cess rate of 74.4%.
The remaining nine patients had a mean MEP of
32.8 ± 2.2; range: 30–37 mmHg, three patients were scores
one on VAS scoring and the other six were scored 2 and on
KED staging, all of the nine patients were staged II, (Table
4, Fig. 4). Patients who had failed PD at the end of 12-m
Table 2 Patients’ enrollment data.
Data Findings
Age (years) Strata <30 Frequency 8 (22.9%)
Mean 25.3 ± 1.8 (23–28)
>30–40 Frequency 9 (25.7%)
Mean 34 ± 2.2 (31–38)
>40–50 Frequency 12 (34.3%)
Mean 45.1 ± 1.7 (41–47)
>50 Frequency 6 (17.1%)
Mean 54.2 ± 2.3 (51–57)
Total Frequency 35 (100%)
Mean 39.5 ± 10.4 (23–57)
Gender Males 20 (57.1%)
Females 15 (42.9%)
Valiukenas Achalasia Severity Scoring 0 0
1 5 (14.3)
2 21 (60%)
3 9 (25.7%)
Kostic staging of the degree of esophageal dilatation I 7 (20%)
II 23 (65.7%)
III 5 (14.3)
Esophageal manometric pressure (mmHg) >45 29 (82.9%)
30–45 6 (17.1%)
<30 0
Table 3 Pneumatic dilatation procedural data.
Parameter Number Value
Procedural time (min) Strata 35–40 12 (34.3%) 37.2 ± 2.4 (35–40)
>40–45 13 (37.2%) 44.1 ± 1.4 (41–45)
>45–50 6 (17.1%) 47.3 ± 2.1 (46–50)
>50–60 4 (11.4%) 56.5 ± 2.9 (53–60)
Total 35 (100%) 43.7 ± 6.4 (35–60)
Time till 1st oral intake (hr) Strata 6–9 14 (40%) 8.3 ± 0.6 (7–9)
>9–12 13 (37.2%) 10.9 ± 1 (10–12)
>12–18 5 (14.3%) 16.2 ± 1.6 (15–18)
>18–24 3 (8.5%) 22.7 ± 2.3 (20–24)
Total 35 (100%) 11.5 ± 4.2 (7–24)
Hospital stay (days) Strata Same day 25 (91.4%)
Next day 10 (8.6%)
Total 35 (100%) 1.3 ± 0.5 (1–2)
Data are presented as mean ± SD & numbers; ranges & percentage are in parenthesis 16511.
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(34.8 ± 9.3; range: 24–47 years) than those had succeeded
PD (39.4 ± 10.8; range: 23–57 years).
Unfortunately, three patients of those had succeeded PD
developed reﬂux esophagitis and planned for laparoscopic
anti-reﬂux surgery. Additionally, the nine patients who had
failed PD trials were planned for laparoscopic Heller’s myot-
omy combined with Dor fundoplication. Mean operative time
was 103.8 ± 19.4; range: 90–120 min, mean time till ﬁrst oral
intake was 41.1 ± 19.4; range: 18–72 h and mean hospital stay
was 2.7 ± 0.8; range: 2–4 days. Two patients had intraopera-
tive mucosal perforation that was immediately repaired and
oral intake was prohibited till oral gastrographin swallow
assured complete healing of the perforation for an intraopera-
tive complication rate of 16.7% (Table 5).All of the nine patients who underwent surgical interference
for recurrent achalasia were followed up for 12 months and six
patients (66.7%) had VAS score of zero, while the other three
had VAS score of one. Seven patients were of KED stage I and
two patients were of stage II. Moreover, seven patients had
mean MEP of 20.6 ± 3.8; range: 15–27 mmHg, while the
remaining two patients had mean MEP of 32 and 34 mmHg,
respectively, for a subjective surgical success rate of 66.7%
and objective success rate of 77.8%.
Comparison of outcome of both modalities showed non-
signiﬁcant (v2 = 0.106, p> 0.05) subjective improvement in
favor of PD, while surgery showed non-signiﬁcant
(v2 = 0.415, p> 0.05) objective improvement compared to
PD, (Fig. 5).
Figure 2 (a) After minimal dissection of the anterior esophagus, a 6–8 cm myotomy is performed using scissors. (b) The myotomy is
extended 1.5–2 cm downwards on the gastric wall using a hook. (c) An anterior hemifundoplication (Dor) procedure is performed without
mobilizing the gastric fundus. (d) Three stitches are inserted on each side: the proximal stitch includes the stomach, the edge of the
myotomy and the diaphragm. (e) Creation of a Dor fundoplication: the ﬁrst suture extends from the anterior portion of the fundus to the
left edge of the myotomy (arrow 1). The second suture will anchor the fundoplication and part of the myotomy in the abdomen by
apposing the fundus (arrow 2) to the left crus (not shown) and then to left edge of the myotomy (arrow 3). (f) Completed Dor
fundoplication: suture line (arrows 1 to 2) anchors the fundoplication to the right edge of the myotomy (M) with stitch (at arrow 2)
incorporates the fundus, the right crus to the right edge of the myotomy. Arrow 3 points the suture that secures the fundoplication to the
diaphragm. Arrow 4 points to the divided short gastric vessels that are brought into an anterior position as the fundoplication is created.
This reinforces the need for a complete mobilization of the gastric fundus for the proper conﬁguration of the fundoplication.
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Figure 4 Patients’ distribution according to number of PD trials
conducted throughout 12-month follow-up.
Table 4 Patients’ distribution according to results of diagnostic pa
Baseline M-1
Valiukenas Achalasia Severity Scoring
0 0 33 (94.3%
1 5 (14.3%) 2 (5.7)
2 21 (60%) 0
3 9 (25.7%) 0
P <0.001
Kostic Staging of the degree of esophageal dilatation
I 7 (20%) 30 (85.7%
II 23 (65.7%) 5 (14.3)
III 5 (14.3) 0
P <0.001
Esophageal manometric pressure
>45 32 (91.4%) 0
30–45 3 (8.6%) 6 (17.1)
<30 0 29 (82.9%
P <0.001
Data are presented as numbers; percentages are in parenthesis; P: signiﬁ
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The current study included 35 patients with well documented
achalasia as approved clinically, endoscopically and using
esophageal manometry. All patients underwent PD as a ﬁrst-
line therapeutic modality. PD provided signiﬁcant advantages
in the form of the short duration of procedure, 25 patients
were managed as one-day procedure and were discharged after
oral resumption and conduction of oral gastrographin swallow
for assurance of release. Thus, PD provided rapid relief of
symptoms and spared the need for anesthesia and surgery with
their concomitant hazards with signiﬁcant reduction of cost
and spare of resources. Concerning outcome, PD provided
subjective and objective success rate at the end of 12-M
follow-up of 74.4% and only nine patients were shifted to sur-
gery and were mostly younger than those had succeeded
PD.(See Table 6)
In line with the obtained results, Boztas et al.16 found PD is
an effective procedure in the treatment of primary achalasia dur-
ing the short- and long-term period and treatment evaluation
can possibly be made objectively with radiographic and mano-
metric alterations of esophagus that occurred after pneumatic
dilatation. Honein et al.17 reported a satisfactory result in
80.5% of their series of achalasia patients after only one or
two sessions of PD and concluded that performing balloon dila-
tation is simple, safe and efﬁcacious for treating patients with
achalasia. Chuah et al.18,19 evaluated the outcome of 33 achala-
sia patients managed using PD and reported excellent results in
27 (81.8%), good results in three (9.1%), and failure in three
(9.1%) and concluded that the technique is effective and a safe
option for achalasia treatment and patients older than 45 years
have favorable overall clinical remissions. Sinn et al.20 reported
that a single PD resulted in a 2-year remission rate of 66%. Ta-
naka et al.21 also, reported that successful PDwas achieved in 41
of 55 (74.5%) patients and concluded that PD is a safe and effec-
tive treatment for achalasia, particularly in older patients who
experience a better outcome than younger patients.
The reported ﬁgure for 12-m follow-up failure rate of PD;
25.6% coincided with Alderliesten et al.22 who reported 5-rameters recorded throughout 12-M follow-up period.
M-3 M-6 M-12
) 32 (91.4) 27 (77.1) 26 (74.3%)
2 (5.7%) 5 (14.3) 3 (8.6)
1 (2.9%) 3 (8.6) 6 (17.1)
0 0 0
<0.001 <0.001 <0.001
) 28 (80%) 26 (74.3%)
7 (20%) 9 (25.7%)
0 0
<0.001 <0.001
0 0 0
8 (16.7%) 9 (25.7) 9 (25.7)
) 27 (77.1%) 26 (74.3%) 26 (74.3%)
<0.001 <0.001 <0.001
cance versus baseline data.
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Figure 5 Mean (+SD) esophageal manometric pressure at end
of 12-M follow-up of studied patients.
Table 6 Follow-up ﬁndings of the nine patients who underwent su
Baseline M-1
Valiukenas Achalasia Severity Scoring
0 0 8 (88.9%
1 3 (8.6) 1 (11.1)
2 6 (17.1) 0
3 0 0
P <0.001
Kostic Staging of the degree of esophageal dilatation
I 0 9 (100%
II 9 (100%) 0
III 0 0
P <0.001
Esophageal manometric pressure
>45 0 0
30–45 9 (100%) 0
<30 0 9 (100%
P <0.001
Data are presented as numbers; percentages are in parenthesis; P: signiﬁ
Table 5 Operative and immediate postoperative data.
Parameter Number Value
Operative time (min) Strata 90–105 7 (58.3%) 95.7 ± 6.1 (90–105)
>105–120 5 (41.7%) 115 ± 5 (100–120)
Total 12 (100%) 103.8 ± 11.3 (90–120)
Time till 1st oral intake (hr) Strata <24 2 (16.7%) 19 ± 1.4 (18–20)
>24–48 6 (50%) 32.7 ± 7.7 (28–48)
>48 4 (33.3%) 64.8 ± 8.6 (55–72)
Total 12 (100%) 41.1 ± 19.4 (18–72)
Hospital stay (days) Strata 2 days 6 (50%)
3 days 4 (33.3%)
4 days 2 (16.7%)
Total 12 (100%) 2.7 ± 0.8 (2–4)
Data are presented as mean ± SD & numbers; ranges & percentage are in parenthesis.
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with classic achalasia, respectively and concluded that PD is
an effective primary treatment in patients with primary achala-
sia, but patients are at increased risk of recurrent disease dur-
ing long-term follow-up, if the disease presented at young age,
or they had classic achalasia, high LES pressure 3 months after
PD and incomplete obliteration of the balloon’s waist during
PD.
Comparison of 12-m outcome after either PD or surgical
showed non-signiﬁcant difference between both modalities
either subjectively or objectively. These data in addition to
the above mentioned advantages of PD indicated the superior-
ity of PD over surgery as a ﬁrst-line therapeutic modality for
classic achalasia. Concerning safety, also there was non-signif-
icant difference between both modalities of management.
In support of these ﬁndings, Gockel et al.23 found that PD
and laparoscopic myotomy will lead to an immediate and sig-
niﬁcant improvement in symptoms, although the two treat-
ment modalities did not differ in their subjective results.
Kostic et al.24 reported that only minor differences emerged
between PD and laparoscopic myotomy when symptoms, dys-
phagia scorings, and quality-of-life assessments were evaluatedrgical interference recorded throughout 12-M follow-up period.
M-3 M-6 M-12
) 7 (77.8) 7 (77.8) 6 (66.7%)
2 (22.2) 2 (22.2) 3 (33.3%)
0 0 0
0 0 0
<0.001 <0.001 <0.001
) 9 (100%) 8 (88.9%) 7 (77.8)
0 1 (11.1) 2 (22.2)
0 0 0
<0.001 <0.001
0 0 0
0 2 (22.2) 2 (22.2)
) 9 (100%) 7 (77.8%) 7 (77.8%)
<0.001 <0.001 <0.001
cance versus baseline data.
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umented that the European Achalasia Trial group reported 2-
year follow-up results indicating that laparoscopic Heller
myotomy was not superior to endoscopic PD and although
the follow-up period was not long enough to reach a convinc-
ing conclusion, it merits the continued use of PD as a generally
available technique in gastroenterology.
As another evidence for the efﬁcacy of PD, Mikaeli et al.26
assessed whether botulinum toxin injection before PD is supe-
rior to PD alone in achalasia patients and found injection of
botulinum toxin before PD does not signiﬁcantly enhance
the efﬁcacy of pneumatic dilatation. Wang et al.27 evaluated
the effect of different approaches in the treatment of achalasia
in China and found PD was superior with a lower clinical re-
lapse rate compared to botulinum toxin injection and in
uncontrolled trials, the effectiveness of PD was 86.6%
(23.9%) versus 94.8% (10.6%) for Heller’s Myotomy with
the main complications of PD being perforation and gastro-
esophageal reﬂux disease.
In conclusion, PD could be considered as safe, effective and
cost-effective therapeutic modality for patients having classic
achalasia with high subjective and objective success rate.
Moreover, PD could spare surgical interference for compli-
cated or recurrent cases and laparoscopic Heller’s myotomy
with Dor fundoplication is an appropriate surgical modality.
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